Is Bionano Genomics profitable in 2026?

No. Bionano's FY2025 revenue was $28.5M against a net loss of about $26.4M as of April 2026 (TTM), following a $112.0M net loss in FY2024. The FY2025 10-K includes going-concern language, and the company relies on cost cuts and financing to fund operations.

Has Bionano Genomics had layoffs?

Yes, extensively. Headcount fell from 426 employees in May 2023 to 95 by April 2026, including a September 2024 reorganization that cut 84 employees, about 45% of staff at the time, as part of roughly $100M in annualized opex removal.

Could AI replace Bionano Genomics' technology?

Not entirely. Bionano's VIA variant-interpretation software is exposed to AI-driven commoditization, but its optical genome mapping hardware, CLIA-certified lab, and CPT reimbursement codes 81195/81354 are hardware and regulation-dependent moats that AI software alone cannot replicate as of 2026.

Who is Bionano Genomics' biggest competitor?

Long-read sequencing platforms Oxford Nanopore and PacBio are the closest rivals for structural-variant detection, while Illumina's dominant short-read NGS ecosystem and traditional cytogenetics remain the entrenched standard-of-care Bionano is trying to displace.

Who owns Bionano Genomics?

Bionano Genomics is a publicly traded company on Nasdaq under ticker BNGO, with no parent company or disclosed controlling shareholder as of 2026. It executed a 1-for-60 reverse stock split effective January 24, 2025, to maintain Nasdaq listing standards.

Will Bionano Genomics run out of cash?

It is a live risk. The company disclosed going-concern language in its FY2025 10-K, held $29.6M in cash at year-end 2025, and management said cash runway into 2027 depends on retiring senior secured convertible debt in May 2026 without further dilution and on revenue growth.

Biotech tools companies · United States

Bionano Genomics

bionanogenomics.com ↗

Sells optical genome mapping systems for genetic disease and cancer diagnostics.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from August 13, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, testing whether revenue accelerates off the 47% CMS reimbursement bump and whether May 2026 debt retires without new dilution

The call

Bionano has real regulatory footing and a growing installed base, but thin cash, ongoing losses, and well-funded sequencing rivals leave its future unsettled.

Bionano Genomics sells equipment that reads DNA in a specific way (optical genome mapping) and has real advantages like government approval, special billing codes, and 370 machines already in hospitals. However, the company is losing nearly as much money as it makes and has shrunk its stock value by two-thirds in one year through repeated emergency fundraising. Bigger competitors like Illumina and newer long-read sequencing companies are building similar or better tools, while Bionano's cash is draining quickly. The one thing that could save the company is if hospitals order way more machines after insurance started paying better for the test in mid-2025, and if Bionano can pay back its debt in May 2026 without selling more stock to investors, but if either of those fails, another round of dilutive financing is almost certain.

Why

AI pressure: None apparent. AI could someday automate variant interpretation software, but the hardware and CLIA lab workflow stay physical and un-automated for now. Could AI do the core job? Only partly.

Bigger players: Illumina short-read sequencing and long-read platforms from PacBio and Oxford Nanopore. Bigger, better-funded sequencing platforms already sell competing workflows that can approximate what optical genome mapping detects. Could a giant copy it? Probably.

What protects it. CLIA-certified lab, CPT reimbursement codes 81195 and 81354, and roughly 370 installed systems make switching costly for existing users.

What would change this call

Bionano's Q2 2026 earnings (Aug 13, 2026) revenue growth vs 5-16% FY guidance. Shows whether CMS reimbursement bump is translating into real customer wins or losses to rivals.
Whether May 2026 debt retirement completes without a new dilutive raise. Signals if cash pressure is forcing worse terms while competitors stay well-capitalized.
Announcement of a permanent CEO hire with commercial background. Indicates whether leadership stability improves ability to defend installed base against PacBio/Nanopore/Illumina.

Key numbers

CMS raised OGM blood cancer test payment 47% to $1,853.22 (2025-12-04)
32 new optical genome mapping systems installed in 2025 (2026-03-23)
Cash and investments of $29.6M at end of FY2025 (2026-03-23)

Named risks

Going-concern language in FY2025 10-K signals doubt about ability to continue operations. Severity: high
History of dilutive financing including a 1-for-60 reverse split in January 2025. Severity: high
Leadership vacuum after May 2026 CEO departure with only an interim CEO in place. Severity: medium
Consumable supply constraints flagged in Q4 2025 could depress 2026 revenue. Severity: medium
Stock trading near 52-week lows with market cap around $10-13M raises delisting risk. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Oxford Nanopore Technologies	contesting	Long-read platform benchmarked against OGM for structural variant detection as of 2024
Pacific Biosciences (PacBio)	contesting	Long-read sequencing frequently compared to OGM in structural variant benchmarking studies
Illumina	gaining on	Dominant short-read NGS ecosystem converging on structural variant detection niche
10x Genomics	contesting	Linked-read synthetic long-read technology competes for same structural variant use case

Questions people ask

Is Bionano Genomics profitable in 2026?: No. Bionano's FY2025 revenue was $28.5M against a net loss of about $26.4M as of April 2026 (TTM), following a $112.0M net loss in FY2024. The FY2025 10-K includes going-concern language, and the company relies on cost cuts and financing to fund operations.
Has Bionano Genomics had layoffs?: Yes, extensively. Headcount fell from 426 employees in May 2023 to 95 by April 2026, including a September 2024 reorganization that cut 84 employees, about 45% of staff at the time, as part of roughly $100M in annualized opex removal.
Could AI replace Bionano Genomics' technology?: Not entirely. Bionano's VIA variant-interpretation software is exposed to AI-driven commoditization, but its optical genome mapping hardware, CLIA-certified lab, and CPT reimbursement codes 81195/81354 are hardware and regulation-dependent moats that AI software alone cannot replicate as of 2026.
Who is Bionano Genomics' biggest competitor?: Long-read sequencing platforms Oxford Nanopore and PacBio are the closest rivals for structural-variant detection, while Illumina's dominant short-read NGS ecosystem and traditional cytogenetics remain the entrenched standard-of-care Bionano is trying to displace.
Who owns Bionano Genomics?: Bionano Genomics is a publicly traded company on Nasdaq under ticker BNGO, with no parent company or disclosed controlling shareholder as of 2026. It executed a 1-for-60 reverse stock split effective January 24, 2025, to maintain Nasdaq listing standards.
Will Bionano Genomics run out of cash?: It is a live risk. The company disclosed going-concern language in its FY2025 10-K, held $29.6M in cash at year-end 2025, and management said cash runway into 2027 depends on retiring senior secured convertible debt in May 2026 without further dilution and on revenue growth.

Timeline

2026-05-12Q1 2026 revenue reported at $6.7M, up 4% YoY, EPS beats consensus
2026-05-06CEO Erik Holmlin departs; interim President/CEO Al Luderer, board chairman, takes over
2026-03-23FY2025 results released; 2026 revenue guidance set at $30M to $33M
2025-12-04CMS raises CPT 81195 OGM reimbursement 47% to $1,853.22 for 2026
2025-01-31$10 million registered direct offering priced at-the-market closes
2025-01-241-for-60 reverse stock split takes effect to maintain Nasdaq listing
2024-11-14Installed base reaches 368 OGM systems as of Q3 2024
2024-09-10Reorganization cuts 84 employees, about 45% of staff at the time
2023-05-01Headcount stood at 426 employees before major restructuring began

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation